Latest Advances in CAR T-Cell Therapy for Lymphomas and Multiple Myeloma

In this episode, Dr Brad Kahl and Dr Noopur Raje discuss the recent advances and emerging data for CAR T-cell therapy in lymphomas and multiple myeloma including the latest evidence from long-term clinical trial follow-up and real-world data, plus new data with CAR T-cell therapies in new lymphoma settings and novel CAR T-cell therapies currently under development for multiple myeloma.

• Lymphomas
  • DLBCL: Real-world outcomes post axi-cel, CAR T vs autologous HSCT
  • FL: Tisa-cel (ELARA), axi-cel (ZUMA-5)
  • MZL: Liso-cel (TRANSCEND FL)
  • MCL: Real-world outcomes post brexu-cel
  • CLL: Liso-cel (TRANSCEND CLL 004)
• Multiple Myeloma
  • Cilta-cel (CARTITUDE-1)
  • Anito-cel (iMMagine-1)
  • GC012F
  • Arlo-cel
  • BMS-986453
  • TriPRIL 

Presenters:

Brad Kahl, MDProfessor of MedicineWashington University St Louis, Missouri

Noopur Raje, MD Director, Center for Multiple MyelomaMassachusetts General Hospital Cancer CenterProfessor of MedicineHarvard Medical SchoolBoston, Massachusetts 

Content based on an online CME program supported by an independent educational grant from Bristol Myers Squibb.

Link to full program: https://bit.ly/3ViR62V